Analysts Set Ascendis Pharma A/S (NASDAQ:ASND) PT at $202.36

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the fourteen analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $202.36.

A number of equities analysts have issued reports on ASND shares. JPMorgan Chase & Co. increased their price target on Ascendis Pharma A/S from $167.00 to $168.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. UBS Group started coverage on shares of Ascendis Pharma A/S in a report on Tuesday, January 7th. They issued a "buy" rating and a $196.00 price target for the company. Morgan Stanley set a $180.00 price target on shares of Ascendis Pharma A/S in a research note on Tuesday, February 18th. Evercore ISI raised their target price on Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a research note on Tuesday, February 18th. Finally, Wedbush reaffirmed an "outperform" rating and set a $181.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, November 15th.

Ascendis Pharma A/S Stock Down 3.2 %

Shares of ASND stock traded down $5.08 during mid-day trading on Friday, reaching $151.51. 436,424 shares of the stock traded hands, compared to its average volume of 493,657. The company has a market cap of $9.19 billion, a price-to-earnings ratio of -21.34 and a beta of 0.64. The stock's fifty day simple moving average is $136.11 and its two-hundred day simple moving average is $133.92. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $158.00.

Remove Ads

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating analysts' consensus estimates of ($1.32) by $0.64. On average, equities research analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several institutional investors have recently added to or reduced their stakes in ASND. Point72 Asia Singapore Pte. Ltd. purchased a new position in Ascendis Pharma A/S in the 4th quarter valued at approximately $28,000. Wilmington Savings Fund Society FSB purchased a new position in shares of Ascendis Pharma A/S in the third quarter valued at $30,000. Jones Financial Companies Lllp raised its stake in shares of Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock valued at $34,000 after purchasing an additional 197 shares during the period. Blue Trust Inc. lifted its holdings in Ascendis Pharma A/S by 415.2% during the 4th quarter. Blue Trust Inc. now owns 407 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 328 shares in the last quarter. Finally, Groupama Asset Managment bought a new position in Ascendis Pharma A/S in the 3rd quarter worth about $60,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.